Patient-Level Meta-analysis of Clofarabine in Acute Lymphoblastic Leukemia.
Child
Humans
Clofarabine
/ therapeutic use
Arabinonucleosides
/ adverse effects
Adenine Nucleotides
/ adverse effects
Recurrence
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/ drug therapy
Acute Disease
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Leukemia, Myeloid, Acute
/ drug therapy
Clinical Trials, Phase II as Topic
Acute lymphoblastic leukemia
Clofarabine
Hematological malignancies
Oncology
Pediatric
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
12 2023
12 2023
Historique:
received:
04
08
2023
accepted:
22
09
2023
medline:
30
10
2023
pubmed:
11
10
2023
entrez:
11
10
2023
Statut:
ppublish
Résumé
Clofarabine monotherapy at a dose of 52 mg/m A systematic literature review was conducted, using the Dr.Evidence software platform, DOC Search, and Embase, to identify clinical trials with patients with R/R ALL who received clofarabine monotherapy at 52 mg/m A total of 754 patients in 12 clinical studies were analyzed including 682 patients with R/R ALL treated with clofarabine monotherapy at 52 mg/m In this meta-analysis, CR duration and median OS in pediatric patients with R/R ALL appeared to be slightly longer than in the phase II study. No new safety signals were identified. Results support the use of clofarabine monotherapy in its approved indication.
Identifiants
pubmed: 37819554
doi: 10.1007/s12325-023-02696-7
pii: 10.1007/s12325-023-02696-7
pmc: PMC10611855
doi:
Substances chimiques
Clofarabine
762RDY0Y2H
Arabinonucleosides
0
Adenine Nucleotides
0
Types de publication
Systematic Review
Meta-Analysis
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
5447-5463Informations de copyright
© 2023. The Author(s).
Références
Coebergh JW, Reedijk AM, de Vries E, et al. Leukaemia incidence and survival in children and adolescents in Europe during 1978–1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42(13):2019–36. https://doi.org/10.1016/j.ejca.2006.06.005 .
doi: 10.1016/j.ejca.2006.06.005
pubmed: 16919768
Ssenyonga N, Stiller C, Nakata K, et al. Worldwide trends in population-based survival for children, adolescents, and young adults diagnosed with leukaemia, by subtype, during 2000–2014 (CONCORD-3): analysis of individual data from 258 cancer registries in 61 countries. Lancet Child Adolesc Health. 2022;6(6):409–31. https://doi.org/10.1016/s2352-4642(22)00095-5 .
doi: 10.1016/s2352-4642(22)00095-5
pubmed: 35468327
American Cancer Society. Key statistics for acute lymphocytic leukemia (ALL). https://www.cancer.org/cancer/acute-lymphocytic-leukemia/about/key-statistics.html . Accessed 1 Nov 2022.
National Cancer Institute. Childhood acute lymphoblastic leukemia treatment. https://www.cancer.gov/types/leukemia/hp/child-all-treatment-pdq . Accessed Nov 2022.
Jeha S, Pei D, Choi J, et al. Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude total therapy study 16. J Clin Oncol. 2019;37(35):3377–91. https://doi.org/10.1200/jco.19.01692 .
doi: 10.1200/jco.19.01692
pubmed: 31657981
pmcid: 7351342
Reedijk AMJ, Coebergh JWW, de Groot-Kruseman HA, et al. Progress against childhood and adolescent acute lymphoblastic leukaemia in the Netherlands, 1990–2015. Leukemia. 2021;35(4):1001–11. https://doi.org/10.1038/s41375-020-01024-0 .
doi: 10.1038/s41375-020-01024-0
pubmed: 32820270
O’Brien S, Thomas D, Ravandi F, et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer. 2008;113(11):3186–91. https://doi.org/10.1002/cncr.23919 .
doi: 10.1002/cncr.23919
pubmed: 18846563
Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–17. https://doi.org/10.1056/NEJMoa1407222 .
doi: 10.1056/NEJMoa1407222
pubmed: 25317870
pmcid: 4267531
DuVall AS, Sheade J, Anderson D, Yates SJ, Stock W. Updates in the management of relapsed and refractory acute lymphoblastic leukemia: an urgent plea for new treatments is being answered! JCO Oncol Pract. 2022;18(7):479–87. https://doi.org/10.1200/op.21.00843 .
doi: 10.1200/op.21.00843
pubmed: 35380890
Cliff ERS, Kelkar AH, Russler-Germain DA, et al. High cost of chimeric antigen receptor T cells: challenges and solutions. Am Soc Clin Oncol Educ Book. 2023;43:e397912. https://doi.org/10.1200/edbk_397912 .
doi: 10.1200/edbk_397912
pubmed: 37433102
Zhenchuk A, Lotfi K, Juliusson G, Albertioni F. Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochem Pharmacol. 2009;78(11):1351–9. https://doi.org/10.1016/j.bcp.2009.06.094 .
doi: 10.1016/j.bcp.2009.06.094
pubmed: 19576186
Long MJC, Zhao Y, Aye Y. Clofarabine commandeers the RNR-α-ZRANB3 nuclear signaling axis. Cell Chem Biol. 2020;27(1):122–133.e5. https://doi.org/10.1016/j.chembiol.2019.11.012 .
doi: 10.1016/j.chembiol.2019.11.012
pubmed: 31836351
Stumpel DJPM, Schneider P, Pieters R, Stam RW. The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia. Eur J Cancer. 2015;51(14):2008–21. https://doi.org/10.1016/j.ejca.2015.06.117 .
doi: 10.1016/j.ejca.2015.06.117
pubmed: 26188848
Jayanthan A, Singh A, Lewis VA, Narendran A. Preclinical studies of cytotoxicity, drug synergy and biological correlates of clofarabine against infant leukemia cells. Blood. 2010;116(21):4342–4342. https://doi.org/10.1182/blood.V116.21.4342.4342 .
doi: 10.1182/blood.V116.21.4342.4342
Jeha S, Gandhi V, Chan KW, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood. 2004;103(3):784–9. https://doi.org/10.1182/blood-2003-06-2122 .
doi: 10.1182/blood-2003-06-2122
pubmed: 14551141
Kantarjian HM, Gandhi V, Kozuch P, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol. 2003;21(6):1167–73. https://doi.org/10.1200/jco.2003.04.031 .
doi: 10.1200/jco.2003.04.031
pubmed: 12637486
Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003;102(7):2379–86. https://doi.org/10.1182/blood-2003-03-0925 .
doi: 10.1182/blood-2003-03-0925
pubmed: 12791647
Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol. 2006;24(12):1917–23. https://doi.org/10.1200/JCO.2005.03.8554 .
doi: 10.1200/JCO.2005.03.8554
pubmed: 16622268
Künz T, Hauswirth AW, Hetzenauer G, Rudzki J, Nachbaur D, Steiner N. Changing landscape in the treatment of adult acute lymphoblastic leukemia (ALL). Cancers. 2022;14(17):4290.
doi: 10.3390/cancers14174290
pubmed: 36077822
pmcid: 9454969
Papadantonakis N, Advani AS. Recent advances and novel treatment paradigms in acute lymphocytic leukemia. Therap Adv Hematol. 2016;7(5):252–69. https://doi.org/10.1177/2040620716652289 .
doi: 10.1177/2040620716652289
Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet. 2020;395(10230):1146–62. https://doi.org/10.1016/s0140-6736(19)33018-1 .
doi: 10.1016/s0140-6736(19)33018-1
pubmed: 32247396
Whitehead A. Meta-analysis of controlled clinical trials. 1st ed. Chichester: Wiley; 2002.
doi: 10.1002/0470854200
Freeman MF, Tukey JW. Transformations related to the angular and the square root. Ann Math Stat. 1950;21(4):607–11.
doi: 10.1214/aoms/1177729756
Koh K, Ogawa C, Okamoto Y, et al. Phase 1 study of clofarabine in pediatric patients with relapsed/refractory acute lymphoblastic leukemia in Japan. Int J Hematol. 2016;104(2):245–55. https://doi.org/10.1007/s12185-016-2004-4 .
doi: 10.1007/s12185-016-2004-4
pubmed: 27086352
Lu A, Fang Y, Du X, et al. Efficacy, safety and pharmacokinetics of clofarabine in Chinese pediatric patients with refractory or relapsed acute lymphoblastic leukemia: a phase II, multi-center study. Blood Cancer J. 2016;6(2):e400. https://doi.org/10.1038/bcj.2016.8 .
doi: 10.1038/bcj.2016.8
pubmed: 26918364
pmcid: 4771971
Suo P, Zhang LP, Wu J, et al. Therapeutic effect of clofarabine in children with relapsed or refractory acute lymphoblastic leukemia. Chin J Contemp Pediatr. 2013;15(6):444–7.
Liu APY, Lee V, Li CK, Ha SY, Chiang AKS. Refractory acute lymphoblastic leukemia in Chinese children: bridging to stem cell transplantation with clofarabine, cyclophosphamide and etoposide. Ann Hematol. 2016;95(3):501–7. https://doi.org/10.1007/s00277-015-2577-7 .
doi: 10.1007/s00277-015-2577-7
pubmed: 26666536
Hijiya N, Thomson B, Isakoff MS, et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood. 2011;118(23):6043–9. https://doi.org/10.1182/blood-2011-08-374710 .
doi: 10.1182/blood-2011-08-374710
pubmed: 21967976
pmcid: 3731655
Gruber T, Pei D, Choi J, et al. Clofarabine treatment of KMT2Ar infantile patients with acute lymphoblastic leukemia in St. Jude total therapy study 16. Blood Adv. 2022;6(24):6131–4. https://doi.org/10.1182/bloodadvances.2022008557 .
doi: 10.1182/bloodadvances.2022008557
pubmed: 36251744
pmcid: 9768237
Pieters R, De Lorenzo P, Ancliffe P, et al. Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the interfant-06 protocol: results from an international phase III randomized study. J Clin Oncol. 2019;37(25):2246–56. https://doi.org/10.1200/jco.19.00261 .
doi: 10.1200/jco.19.00261
pubmed: 31283407
Hilden JM, Dinndorf PA, Meerbaum SO, et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children’s Oncology Group. Blood. 2006;108(2):441–51. https://doi.org/10.1182/blood-2005-07-3011 .
doi: 10.1182/blood-2005-07-3011
pubmed: 16556894
pmcid: 1895499
Pieters R, Schrappe M, De Lorenzo P, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet. 2007;370(9583):240–50. https://doi.org/10.1016/s0140-6736(07)61126-x .
doi: 10.1016/s0140-6736(07)61126-x
pubmed: 17658395
Faderl S, Wetzler M, Rizzieri D, et al. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. J Clin Oncol. 2012;30(20):2492–9. https://doi.org/10.1200/jco.2011.37.9743 .
doi: 10.1200/jco.2011.37.9743
pubmed: 22585697
pmcid: 4874149
Andersson BS, Thall PF, Ma J, et al. A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation. Bone Marrow Transpl. 2022;57(8):1295–303. https://doi.org/10.1038/s41409-022-01705-7 .
doi: 10.1038/s41409-022-01705-7
Rubnitz JE, Lacayo NJ, Inaba H, et al. Clofarabine can replace anthracyclines and etoposide in remission induction therapy for childhood acute myeloid leukemia: the AML08 multicenter, randomized phase III trial. J Clin Oncol. 2019;37(23):2072–81. https://doi.org/10.1200/jco.19.00327 .
doi: 10.1200/jco.19.00327
pubmed: 31246522
pmcid: 7001777
Kearns P, Michel G, Nelken B, et al. A European phase II study (BIOV-111) of clofarabine (Evoltra®) in refractory and relapsed childhood acute lymphoblastic leukemia: final results. Blood. 2007;110(11):11–11. https://doi.org/10.1182/blood.V110.11.11.11 .
doi: 10.1182/blood.V110.11.11.11
Choi JY, Hong CR, Hong KT, et al. Effectiveness and safety of clofarabine monotherapy or combination treatment in relapsed/refractory childhood acute lymphoblastic leukemia: a pragmatic, non-interventional study in Korea. Cancer Res Treat. 2021;53(4):1184–94. https://doi.org/10.4143/crt.2020.289 .
doi: 10.4143/crt.2020.289
pubmed: 33421973
pmcid: 8524030
O’Connor D, Sibson K, Caswell M, et al. Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia. Br J Haematol. 2011;154(4):482–5. https://doi.org/10.1111/j.1365-2141.2011.08752.x .
doi: 10.1111/j.1365-2141.2011.08752.x
pubmed: 21689087
Trioche P, Nelken B, Michel G, et al. French “real life” experience of clofarabine in children with refractory or relapsed acute lymphoblastic leukaemia. Exp Hematol Oncol. 2012;1(1):39. https://doi.org/10.1186/2162-3619-1-39 .
doi: 10.1186/2162-3619-1-39
pubmed: 23227903
pmcid: 3599405
Specified Drug Use Surveillance for effectiveness evaluation of Evoltra monotherapy in Japanese Patients with Refractory/Relapsed Acute Lymphoblastic Leukemia. Available at: https://www.sanofi.com/assets/dotcom/content-app/clinical-studies/pharma/Letter-C/CLOFAL07263--OBS15639--results-summary-SA-com.pdf .
The Evoltra® European Registry Programme: Pediatric Leukemia. Available at: https://www.sanofi.com/assets/dotcom/content-app/clinical-studies/pharma/Letter-C/CLO08708--OBS12879--results-summary-SA-com.pdf .